{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:16:14Z","timestamp":1762118174265,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["UM1AI106716"],"award-info":[{"award-number":["UM1AI106716"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI068616","UM1AI068632"],"award-info":[{"award-number":["UM1AI068616","UM1AI068632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.contraception.2021.08.006","type":"journal-article","created":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T17:49:12Z","timestamp":1629049752000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens"],"prefix":"10.1016","volume":"105","author":[{"given":"Regis","family":"Kreitchmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Stek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8569-2293","authenticated-orcid":false,"given":"Brookie M.","family":"Best","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-0505","authenticated-orcid":false,"given":"Edmund","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiaJia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahida","family":"Chakhtoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-1502","authenticated-orcid":false,"given":"Mark","family":"Mirochnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahizechukwu C.","family":"Eke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2021.08.006_bib0001","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cnur.2020.06.005","article-title":"Update on Clinical Practice Guidelines for Human Immunodeficiency Virus","volume":"55","author":"Pitts","year":"2020","journal-title":"The Nursing clinics of North America"},{"issue":"10","key":"10.1016\/j.contraception.2021.08.006_bib0002","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s40262-020-00915-w","article-title":"Innovative approaches for pharmacology studies in pregnant and lactating women: a viewpoint and lessons from HIV","volume":"59","author":"Eke","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2021.08.006_bib0003","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 2020 fact sheet. 2020."},{"key":"10.1016\/j.contraception.2021.08.006_bib0004","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0970-0218.158855","article-title":"Contraceptive Use and Unintended Pregnancies Among HIV-Infected Women in Mumbai","volume":"40","author":"Joshi","year":"2015","journal-title":"Indian journal of community medicine: official publication of Indian Association of Preventive & Social Medicine"},{"key":"10.1016\/j.contraception.2021.08.006_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2016.03.011","article-title":"Typical-use contraceptive failure rates in 43 countries with Demographic and Health Survey data: summary of a detailed report","volume":"94","author":"Polis","year":"2016","journal-title":"Contraception"},{"issue":"11","key":"10.1016\/j.contraception.2021.08.006_bib0006","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1093\/humrep\/dew222","article-title":"WHO study group on subdermal contraceptive implants for women. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant","volume":"31","author":"Ali","year":"2016","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.contraception.2021.08.006_bib0007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/14730782.2000.12288981","article-title":"The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant","volume":"5","author":"Bennink","year":"2000","journal-title":"The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception"},{"key":"10.1016\/j.contraception.2021.08.006_bib0008","unstructured":"FDA. Implanon\u2122 (Etonogestrel 68 mg subdermal implant)."},{"key":"10.1016\/j.contraception.2021.08.006_bib0009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0010-7824(98)00110-3","article-title":"Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon","volume":"58","author":"Wenzl","year":"1998","journal-title":"Contraception"},{"issue":"14","key":"10.1016\/j.contraception.2021.08.006_bib0010","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/QAD.0000000000001591","article-title":"Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy","volume":"31","author":"Chappell","year":"2017","journal-title":"AIDS"},{"issue":"13","key":"10.1016\/j.contraception.2021.08.006_bib0011","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/QAD.0000000000002308","article-title":"Partners PrEP Study Team. A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda","volume":"33","author":"Patel","year":"2019","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.contraception.2021.08.006_bib0012","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/QAI.0000000000000134","article-title":"Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women","volume":"66","author":"Landolt","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2021.08.006_bib0013","first-page":"12","article-title":"Unintended Pregnancy and Its Adverse Social and Economic Consequences on Health System: A Narrative Review Article","volume":"44","author":"Yazdkhasti","year":"2015","journal-title":"Iranian journal of public health"},{"key":"10.1016\/j.contraception.2021.08.006_bib0014","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1783\/147118907782101724","article-title":"Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz","volume":"33","author":"Matiluko","year":"2007","journal-title":"The journal of family planning and reproductive health care"},{"issue":"4","key":"10.1016\/j.contraception.2021.08.006_bib0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/QAI.0000000000000189","article-title":"Effect of antiretroviral therapy including lopinavir\/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women","volume":"66","author":"Vieira","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"10.1016\/j.contraception.2021.08.006_bib0016","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1016\/S2352-3018(19)30155-9","article-title":"AIDS Clinical Trials Group A5316 Study Team. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study","volume":"6","author":"Scarsi","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.contraception.2021.08.006_bib0017","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1128\/AAC.00337-06","article-title":"Impact of sample size on the performance of multiple-model pharmacokinetic simulations","volume":"50","author":"Tam","year":"2006","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"3","key":"10.1016\/j.contraception.2021.08.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02168-20","article-title":"Population pharmacokinetics of tenofovir in pregnant and postpartum women using tenofovir disoproxil fumarate","volume":"65","author":"Eke","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.contraception.2021.08.006_bib0019","unstructured":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. 2014."},{"key":"10.1016\/j.contraception.2021.08.006_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.contraception.2012.08.002","article-title":"Contraception technology: past, present and future","volume":"87","author":"Sitruk-Ware","year":"2013","journal-title":"Contraception"},{"issue":"11","key":"10.1016\/j.contraception.2021.08.006_bib0021","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(15)00184-8","article-title":"Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study","volume":"2","author":"Patel","year":"2015","journal-title":"Lancet HIV"},{"year":"2015","series-title":"Medical eligibility criteria for contraceptive use: A WHO family planning cornerstone","key":"10.1016\/j.contraception.2021.08.006_bib0022"},{"key":"10.1016\/j.contraception.2021.08.006_bib0023","doi-asserted-by":"crossref","first-page":"e4165","DOI":"10.1002\/bmc.4165","article-title":"Simultaneous determination of etonogestrel and ethinyl estradiol in human plasma by UPLC-MS\/MS and its pharmacokinetic study","volume":"32","author":"Nair","year":"2018","journal-title":"Biomedical chromatography: BMC"},{"key":"10.1016\/j.contraception.2021.08.006_bib0024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40262-014-0204-8","article-title":"Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives","volume":"54","author":"Tittle","year":"2015","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.contraception.2021.08.006_bib0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/14787210.6.6.785","article-title":"Atazanavir: its role in HIV treatment","volume":"6","author":"Wood","year":"2008","journal-title":"Expert review of anti-infective therapy"},{"issue":"5","key":"10.1016\/j.contraception.2021.08.006_bib0026","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1476-5381.2010.00759.x","article-title":"Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1\/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir","volume":"160","author":"van Waterschoot","year":"2010","journal-title":"Br J Pharmacol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782421003504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782421003504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:11:23Z","timestamp":1762117883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782421003504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"alternative-id":["S0010782421003504"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2021.08.006","relation":{},"ISSN":["0010-7824"],"issn-type":[{"type":"print","value":"0010-7824"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2021.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}